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The blood-brain barrier (BBB) consists of a continuous layer of endothelial cells joined by tight junctions at the cerebral vasculature. It represents a physical and enzymatic barrier to restrict and regulate the penetration of compounds into and out of the brain and maintain the homeostasis of the brain microenvironment. Brain penetration is essential for compounds where the site of action is within the central nervous system (CNS), while BBB penetration needs to be minimized for compounds that target peripheral sites to reduce potential CNS-related side effects. Therefore, it is critical during the drug discovery phase to design and select compounds having appropriate brain penetration properties for drug targets that reside within and outside the CNS (Chen et al., 2003a; Golden and Pollack, 2003) .
The kinetics of brain penetration consists of the extent of brain equilibrium and the time to achieve brain equilibrium. The extent of brain equilibrium is often quantified by brain-plasma partition coefficient (K p ), the ratio of total brain concentration and plasma concentration at steady state. This parameter depends upon drug binding in plasma and brain tissue, the uptake and efflux transporters at BBB, metabolism in the brain and the bulk flow of cerebrospinal fluid (Hammarlund-Udenaes et al., 1997) . If active transporters, brain metabolism and the bulk flow of cerebrospinal fluid do not contribute significantly to brain drug disposition, the free drug concentration in brain equals to the free drug concentration in plasma and the K p equals to the ratio of unbound fraction in plasma and unbound fraction in brain at equilibrium.
Theoretically, the ratio of unbound brain concentration and unbound plasma concentration at steady state, K p,free , is a better parameter to quantitate the extent of brain equilibrium (Tunblad et al., 2003) . This parameter is not dependent upon plasma and brain tissue binding. In drug discovery it is important to identify CNS targeted compounds with K p,free of unity by screening out substrates of efflux transporters.
Extensive screening efforts have been made in the drug discovery phase to identify the substrates of known efflux transporters, such as P-glycoprotein (P-gp) (Adachi et al., 2001; Polli et al., 2001; Chen et al., 2003b; Lin and Yamazaki, 2003) .
Although the extent of brain penetration or achievement of high free brain concentration is the most critical property, the time to reach brain equilibrium is another important perspective of the kinetics of brain penetration. In CNS drug discovery, it is often desirable to identify compounds that can quickly penetrate into brain thereby the unbound drug concentration at the targeted site in brain tissue can reach plasma unbound concentration quickly after administration. The property of quick brain penetration can be This article has not been copyedited and formatted. The final version may differ from this version. gauged by the time to reach brain equilibrium. Therefore, a short time to achieve brain equilibrium is a surrogate for a rapid achievement of active brain concentration. Rapid CNS penetration becomes essential for the compounds used for many diseases such as hypnosis (Hardman et al., 2001) , status epilepsy (Li et al., 2000) , and stroke (Adams and Leira, 1998) . Empirical approaches to identify compounds with quick brain penetration during the discovery phase include screens to identify compounds with high BBB permeability (Di et al., 2003; Liu et al., 2004) . In addition to BBB permeability, it has been implied in the literature that the time of brain equilibrium also depends upon the partition coefficient (HammarlundUdenaes et al., 1997) . No study has been conducted to evaluate systematically the factors that determine the time to reach brain equilibrium.
The present study was designed to evaluate the effects of BBB permeability, plasma protein binding, and brain tissue binding on the time to reach brain equilibrium. The application of the results from the present study on strategies to select rapid brain penetration compounds in drug discovery is also discussed.

MATERIALS AND METHODS
Chemicals. Caffeine, fluoxetine, propranolol, theobromine, and theophylline were obtained from Sigma-Aldrich (St. Louis, MO) . N[3-(4'-fluorophenyl)-3-(4'-phenylphenoxy)propyl]sarcosine (NFPS) and methoxy-3-[(2-phenyl-piperadinyl-3-amino)-methyl]-phenyl-N-methyl-methane-sulfonamide (CP-141938) were synthesized at Pfizer Global Research and Development Laboratories (Groton, CT) with purity greater than 98%. All other chemicals used in the experiments were of the highest available grade.
Animal Experiments. Male Sprague-Dawley rats (250-280 g) were obtained from Charles River (Raleigh, NC). They were housed at controlled temperature and humidity in an alternating 12-h light and dark cycle with free access to food and water. Rats received caffeine (10 mg/kg), CP-141938 (5 mg/kg), fluoxetine (10 mg/kg), NFPS (10 mg/kg), propranolol (5 mg/kg), theobromine (10 mg/kg), or theophylline (10 mg/kg) subcutaneously. The doses were prepared in 0.9% saline and delivered in a volume of 2 mL/kg.
Blood samples were collected in heparin treated tubes at designated time between 10 min and 24 h post dose via cardiac puncture. After centrifugation (3000 rpm, 10 min) of the blood, plasma was isolated. Brain tissue was harvested and rinsed with saline immediately after collection. The plasma and brain samples were stored at -20°C prior to analysis.
Protein Binding. The unbound fraction in plasma and brain homogenate was determined using a 96-well equilibrium dialysis method reported previously (Kalvass and Maurer, 2002) . Briefly, fresh Sprague-Dawley rat plasma and brain tissue were obtained on the day of the study. Brain tissue was homogenized in two volumes (w/v) of 100 mM sodium phosphate buffer. Plasma, brain homogenate, and phosphate buffer (for equilibrium controls) were spiked with a compound (500 ng/mL) and 150 µL of these matrices were added to the dialysis apparatus. The receiver side contained 150 µL of phosphate buffer. The 96-well equilibrium dialysis apparatus was maintained on a shaking device in an incubator at 37°C for 5 h.
Ten µL of plasma or brain homogenate and 50 µL of buffer were taken from the apparatus and added to high performance liquid chromatography (HPLC) vials containing 100 µL of acetonitrile. The samples were then vortexed, centrifuged and the supernatant was stored at -20°C prior to analysis. The unbound fractions determined from diluted brain tissue homogenates was corrected to yield an estimate of unbound fraction in the intact brain tissue using a previously published method (Kalvass and Maurer, 2002) . The HPLC-MS/MS system consisted of either a Shimadzu ternary pump (Shimadzu LC-10A, Kyoto, Japan) or an Agilent quaternary pump HPLC system (Hewlett Packard, Palo Alto, CA), an autosampler and a PE Sciex API 3000 or 4000 (Perkin-Elmer Sciex Instruments, Foster City, CA) mass spectrometer with a turbo ion spray interface (PE-Sciex, Thornhill, Ontario, Canada). A 10-µL aliquot of each sample was injected onto a HPLC column. CP-141938 was run on a Phenomenex Synergi Polar column (50x4.6 mm, 4µm, Phenomenex, Torrance, CA) isocratically at 75% acetonitrile and 25% 5 mM ammonium acetate containing 0.01% formic acid and 0.1% isopropranol with a flow rate of 1 ml/min for 4 min. Propranolol, Fluoxetine, and NFPS were run on a Phenomenex Primesphere C18 HC column (30x2.0 mm, 5 µm, Phenomenex, Torrance, CA) using a gradient pump program beginning at 5-10% acetonitrile and 90-95% aqueous 5-20 mM ammomium acetate containting 0.1% isopropranol with a flow rate of 0.4 mL/min. The acetonitrile increased linearly from 10% to 90% from 1.0 to 1.2 min and then maintained at 90% from 1.2 to 4.0 min. The system returned to the initial conditions in a single step and was allowed to equilibrate for 1 min. Caffeine, theobromine, and theophylline were run on a Phenomenex Luna Phenyl Hexyl column (50x4.6mm, 5 µm, Phenomenex, Torrance, CA) isocratically at 20% acetonitrile and 80% 5 mM ammonium acetate containing 0.1% formic acid and 0.1% isopropranol for 5 min at a flow rate of 1 mL/min. All analytes were eluted between 1 and 4 min. quantitation for the plasma samples of caffeine, CP-141938, fluoxetine, NFPS, propranolol, theobromine, and theophylline was 10, 1, 2.5, 1, 2, 50, and 50 ng/mL, respectively. The low limit of quantitation for the brain samples was 40, 4, 10, 4, 5, 200 , and 200 ng/mL, respectively. The relative accuracy was between 80% and 120%.
The contribution of residual blood in the brain tissue to the brain concentration was corrected by subtracting 3.7% of the plasma concentration from the corresponding brain concentration (Khor et al., 1991 ).
Brain PBPK Model.
A hybrid brain PBPK model was constructed based upon a previously published whole-body PBPK model (Peng et al., 2001) . The brain consists of two compartments, i.e., brain intravascular and extravascular compartments ( Figure 1A ). This model was based upon following assumptions: (1) only the unbound drug in vascular space is available to cross the BBB and the unbound and bound compound equilibrates instantaneously within each compartment, (2) no transporter contributes significantly to the brain disposition, consequently, the uptake and efflux clearance equals to PS, the product of BBB permeability-surface area product representing the distribution clearance across BBB via passive diffusion, and (3) cerebrospinal fluid does not significantly impact on the brain drug disposition (Wang et al., 1997) .
The plasma of the hybrid PBPK model consists of one compartment for all compounds except fluoxetine. The plasma of fluoxetine consists of a central compartment and a peripheral compartment. It is assumed that the elimination only occurs in the central compartment.
For caffeine, CP-141938, NFPS, theobromine, and theophylline their mass balance rate equation for the central compartment consisting rapid perfusion organs is:
where V p (mL/kg) is distribution volume of central compartment, C a (ng/mL) is the concentration in central
) is absorption rate constant, X dose (ng/kg) is the dose administered, Cl p (mL/h/kg) is systemic clearance, Q (mL/h/kg) is cerebral blood flow, and C iv (ng/mL) is concentration in the intravascular space in brain. For propranolol:
For fluoxetine:
where Cl d (mL/h/kg) is distribution clearance between central and peripheral compartment and C sp (ng/mL) is concentration in peripheral compartment. The initial conditions for Equation 1, 2, 3, and 4 is C a = 0, X dose = dose, C a = dose/V p , C a = dose/V p , respectively.
Its mass balance rate equation for the peripheral compartment consisting slow perfusion organs is:
where V sp (mL/kg) is distribution volume of the peripheral compartment.
The mass balance rate equation for brain intravascular compartment is:
where V iv (mL/kg) is physiological volume of intravascular space in brain, f u,plasma is unbound fraction in plasma determined using equilibrium dialysis, C ex (ng/mL) is concentration in extravascular space, and K p is equilibrium brain/plasma partitioning coefficient:
The mass balance rate equation for brain extravascular compartment is:
where V ev (mL/kg) is physiological volume of extravascular space. The initial conditions for Equation 5, 6, and 7 is C sp = 0, C iv = 0, and C ev = 0, respectively. The Q, V ev , and V iv was assumed to be 312 mL/h/kg, 6.56 mL/kg, and 0.24 mL/kg, respectively (Peng et al., 2001) Information Criterion (Akaike, 1976) , the degree of co-linearity of parameters, the degree of bias in residual error, the standard error of parameter estimates, and visual inspection of the generated curves relative to the data. A weighting scheme of 1/Y Predicted was used for all fitting procedures (Liu et al., 1999 
where k 12 is rate constant from central (plasma) compartment to peripheralcompartment, k 21 is the rate constant from peripheralcompartment to central compartment, k 10 is the elimination rate constant from plasma compartment (Gibaldi and Perrier, 1982) . By definition, k 12 = Cl d /V p , k 21 = Cl d /V sp , and k 10 = Cl p /V p .
Relationship between Brain and Plasma Concentrations. In order to obtain an explicit expression to describe the BP-time course, the brain PBPK model was simplified by removing the cerebral blood flow from the model under the assumption that BBB permeability is the rate-limiting step for brain penetration ( Figure 1B ) (Hammarlund-Udenaes et al., 1997) . Since brain tissue weight is less than 1% of body weight in rats (Brown et al., 1997) , the amount of drug in brain tissue is much less than that in the rest of the body. Therefore, the impact of efflux of drug from brain on plasma concentration can be considered negligible. After a compound is administrated by an intravenous bolus injection, the mass balance rate equation for plasma can be described as:
The mass balance rate equation for brain tissue can be described as:
Equation 10 where V b (mL/kg) is volume of brain tissue, C b (ng/mL) is concentration in brain compartment. 
According to Equation 13, compounds can be separated into two classes. For Class I compounds, their k out is less than k el . Their BP increases over time after a single dose and cannot reach a plateau. Their brain terminal t 1/2 is longer than the plasma t 1/2 . For Class II compounds, their k out is greater than k el . Their BP increases initially and then reaches a plateau and the terminal t 1/2 of the brain concentration equals to the plasma t 1/2 . From Equation 13 the equilibration time can be quantified with a parameter, equilibration half-life (t 1/2eq ), which is defined as the time to reach 50% of BP at equilibrium. It can be calculated by following formula:
If the plasma concentration maintains constant by an intravenous bolus loading dose and a constant intravenous infusion maintaining dose, the C p will be constant (Patlak and Pettigrew, 1976) This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. 
RESULTS
The PS values of caffeine, CP-141938, fluoxetine, NFPS, propranolol, theobromine, and theophylline determined previously using the in situ rat brain perfusion method are presented in Table 1 ( Liu et al., 2004) . The unbound fractions in rat plasma (f u,plasma ) and brain homogenate (f u,brain ) measured by an equilibrium dialysis method are also presented in Table 1 . The determined unbound fraction in rat plasma is consistent with the values reported in the literature (Bonati et al., 1984; Chauvelot-Moachon et al., 1988; Yasuhara and Levy, 1988; Shum and Jusko, 1989; Caccia et al., 1990) . We observed an inverse relationship between permeability and the nonspecific binding in brain homogenate for some of the model is the physiological volume of rat brain, 6.56 mL/kg body weight (Peng et al., 2001) . Plasma elimination rate constants (k el ) for all compounds except fluoxetine were determined from Cl p /V p , where the Cl p and V p were calculated from the PBPK model. The terminal k el of fluoxetine was estimated from Cl p , Cl d , V p , and V sp using Equation 8. All the pharmacokinetic parameters are shown in Table 2 and 3. Large variability of the estimated PS values for caffeine and theobromine was observed. This is likely due to the lack of data points before plasma and brain reached equilibrium (Figure 2 ). The PBPK model was able to describe the BP values for all the data except the last time point (7 h) for CP-141938 (Figure 2 ). was assigned as greater than 24 h. The t 1/2eq and t 1/2eq,in values were obtained using Equation 14 and 16, respectively (Table 3) . Figure 3A 
Determination of Brain Equilibrium
Correlation of Pharmacokinetic Parameters. The relationship of in vivo logPS and the in situ logPS is presented in
DISCUSSION
There has been a notion that a compound with high BBB permeability will in turn lead to rapid brain penetration. It was also implied in the literature that partition coefficient may play a role in the time to reach brain equilibrium (Hammarlund-Udenaes et al., 1997). However, the exact contribution of BBB permeability, plasma binding, and brain tissue binding on the time to equilibrium has not been assessed systemically. Caffeine, CP-141938, fluoxetine, NFPS, propranolol, theobromine, and theophylline were selected as the model compounds because they displayed a marked differences in their BBB permeability (160-fold), unbound fraction in plasma (14-fold) and brain tissue (560-fold).
The present study demonstrates the utility of using a hybrid brain PBPK model to calculate kinetic parameters that are directly related to physiological processes (Gibaldi and Perrier, 1982) . The hybrid brain PBPK model instead of a whole-body PBPK model was used in the present study because the objective of this work was to examine the effects of plasma binding, brain tissue binding, and BBB permeability on the brain equilibrium time. The brain PBPK model describes the observed brain and plasma concentration-time course data and BP-time course data well except the last data point for CP-141938 (Figure 2 ). This may be due to an experimental variability or slow equilibrium compartments within brain tissue as suggested previously for another P-gp substrate (Chen and Pollack, 1998) . The calculated in vivo logPS from the PBPK model correlates with the determined logPS using an in situ brain perfusion method (R 2 = 0.83, Figure 3A ). This study is consistent with a previous study in which Takasato et al. (1984) showed that in vivo PS values of eight solvent-like compounds using pharmacokinetic analysis were consistent with the in situ PS values (Rapoport et al., 1979) . In addition, the calculated in vivo logf u,brain from the PBPK model also correlates with the determined logf u,brain determined in brain homogenate ( Figure 3B , R 2 = 0.69).
However, the data points are clustered at the extremes of the range and more studies are needed to evaluate the correlation.
The present study demonstrates theoretically and experimentally that the time to equilibrium is governed by the product of PS and f u,brain . The time to equilibrium can be assessed by the time to reach the plateau of BP-time profiles (Figure 2 ) (Rapoport et al., 1982 ). Its BP kept increasing up to 24 h post dose and its brain terminal t 1/2 was longer than its plasma t 1/2 (Figure 2 ). For the Class II compounds, their k out is greater than k el . Their BP increases initially and then reaches a plateau and the terminal t 1/2 of the brain concentration equals to the plasma t 1/2 . The BP-time profile after a single dose is similar to the plasma concentration-time profile after an intravenous infusion (Equation 13) (Gibaldi and Perrier, 1982) . Six of the seven compounds belong to the Class II compounds. Their k out is greater than k el and their BP increased after administration then reached a plateau approximately between 10 min and 2 h. Their brain and plasma t 1/2 values were similar (Table 2 and Figure 2 ).
For Class II compounds, the time to reach equilibrium can be quantified with brain equilibration half-life (t 1/2eq ), which is defined as the time for BP to reach 50% of its plateau level after single intravenous bolus dose. A similar approach has been used in literature to describe the rate of penetration into cerebrospinal fluid (Brodie et al., 1960) . The t 1/2eq calculated using Equation 14 is consistent with the visually observed t 1/2eq (Obs. t 1/2eq ) from the BP-time profiles (Table 3) . Because t 1/2eq is only applicable to Class II compounds, we propose using the intrinsic brain equilibrium half-life (t 1/2eq,in ) to describe the time to equilibrium. The t 1/2eq,in is defined as the time for BP to reach 50% of its plateau level under the condition of constant plasma concentration (Patlak and Pettigrew, 1976) . According to Equation 16, t 1/2eq,in is inversely proportional to the product of PS and f u,brain . Compounds having the same PS•f u,brain should exhibit the same time to reach brain equilibrium. These predictions were in agreement with the simulated data.
The experimental results from this study also support that t 1/2eq,in is determined by the product of PS and f u,brain . Logt 1/2eq,in does not correlate with in situ logPS (R 2 < 0.01), however, a correlation was observed between the in vivo logt 1/2eq,in and log(PS•f u,brain ) (R 2 = 0.85, Figure 4A ). In our theoretical analyses, it was assumed that a transporter does not contribute significantly to brain drug disposition, nevertheless it can be demonstrated that the effect will be the same if transporters do contribute to the disposition, in which case the efflux clearance from brain to plasma instead of PS should be used.
There is an apparent inverse relationship of PS and f u,brain for some of the model compounds. CP-141938 and theobromine have a low PS but high f u,brain , fluoxetine and propranolol have a high PS but low f u,brain (Table 1 and The inverse relationship between PS and f u,brain suggests that to search for rapid brain penetration compounds in drug discovery both PS and f u,brain or the product of PS and f u,brain should be considered. A lead compound should not be eliminated as a candidate compound with quick onset of action only because it shows low permeability. For example, theobromine is a low PS (23 mL/h/kg) and high f u,brain (0.61) compound, resulting in PS•f u,brain of 14 mL/h/kg. In contrast, fluoxetine is a high PS (619 mL/h/kg) and low f u,brain (0.00094) compound, results in PS•f u,brain of 0.6 mL/h/kg. As expected from the PS•f u,brain but not from the PS, the observed t 1/2eq,in for theobromine (~0.1 h) was shorter than that of fluoxetine (~1 h).
The theoretical analysis and PBPK simulation in this study demonstrate that plasma protein binding only determines the total brain drug concentration, not the equilibration time (Equation 16).
Interestingly, logf u,plasma correlates with logf u,brain for the seven model compounds (R 2 = 0.91, Figure 3C ). This apparent correlation is also supported by literature data. For a set of 18 compounds (Kalvass and Maurer, 2002) , logf u,plasma correlates with logf u,brain after two outliers (compound 4 and 8) were removed (R 2 = 0.60). In addition, a good correlation was also observed for 32 compounds (R 2 = 0.85) (Maurer et al., 2004) . Hence, in theory, plasma protein binding per se is not related to the time to equilibrium and should not be considered as a criterion to select rapid brain equilibrium compounds in drug discovery. However, due to the empirical correlation between plasma binding and brain tissue binding, low plasma protein binding may be used as a surrogate. b Liu et al (2004) c Unbound fraction in brain tissue determined using brain homogenate d Doran et al (2005) e Smith et al (2001) f Unpublished data Table 1 . PS values and unbound fraction of seven model compounds in rat plasma and brain tissue (Mean ± SD, n = 4). 
